

Review Form 1.6

Journal Name:	Asian Journal of Research in Infectious Diseases
Manuscript Number:	Ms_AJRID_89851
Title of the Manuscript:	PANGENOTYPIC HCV THERAPY WITH DIRECT ACTING ANTIVIRAL: A SOUTHERN NIGERIA PILOT EXPERIENCE.
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajrid.com/index.php/AJRID/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	To justify the statement of 'The high price of DAAs has restricted their use 'need to be substantiated quoting the cost of management of each case. Mention if this study examined whether generic DAAs could be cost-saving and how long it would take for the treatment to become cost-saving/effective in Nigeria.	
Minor REVISION comments	Availability of directly acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection in India, at much cheaper price.	
Optional/General comments	An innovative experimental approach. More developing countries could learn from it	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Suresh Kishanrao
Department, University & Country	Karnataka State Rural Development and Panchayat Raj University, (KSRDPRU), India